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Introduction
Systemic	lupus	erythematosus	(SLE)	is	a	systemic	autoimmune/inflammatory	disorder	that	can	affect	any	organ	system.	The	disease	presentation,	clinical	course	and	outcome	vary	significantly	between	individuals,	ethnicities
and	age	groups.	Variable	presentations	are	reflected	by	the	11	American	College	of	Rheumatology	(ACR)	classification	criteria	for	SLE,	four	of	which	need	to	be	fulfilled	for	a	patient	to	be	classified	as	having	SLE	[1,2].
The	pathophysiology	of	SLE	is	not	fully	understood.	Familial	clusters,	the	relatively	high	prevalence	of	disease	concordant	monozygotic	twins	and	poor	prognosis	of	individuals	of	African	or	Asian	descent	independent	of	their
current	location	indicate	a	key	contribution	of	heritable	genetic	predisposition	to	disease	expression	[2–6].	The	observation	that	gender	distribution	varies	between	age	groups	with	almost	equal	risk	for	boys	and	girls	under	5	years	of
age,	a	4-	to	5-fold	higher	prevalence	in	girls	under	the	age	of	16	years	and	a	female-to-male	ratio	of	10:1	in	the	adult	age	group	are	a	strong	demographic	indicator	that	hormonal	factors	are	a	central	contributor	to	disease	expression
in	SLE	[2,7].	Finally,	environmental	factors	including	infections,	medication	and	UV	irradiation	play	a	role	in	the	pathophysiology	of	SLE	in	genetically	predisposed	individuals,	where	they	appear	to	contribute	to	the	breach	of	self-
tolerance,	enhancement	of	pre-existing	but	sub-clinical	inflammation	and	the	development	of	tissue	damage	[2,3]	(Fig.	1).
4
Juvenile-onset	systemic	lupus	erythematosus	(jSLE)	–	Pathophysiological	concepts	and	treatment	options
Christian	M.	Hedricha,	b,	∗
christian.hedrich@liverpool.ac.uk
Eve	M.D.	Smitha,	b
Michael	W.	Beresforda,	b
aDepartment	of	Women's	&	Children's	Health,	Institute	of	Translational	Medicine,	University	of	Liverpool,	Liverpool,	UK
bDepartment	of	Paediatric	Rheumatology,	Alder	Hey	Children's	NHS	Foundation	Trust	Hospital,	Liverpool,	UK
∗Corresponding	author.	Department	of	Women's	&	Children's	Health,	Institute	of	Translational	Medicine,	University	of	Liverpool,	Institute	in	the	Park	at	Alder	Hey	Children's	NHS	Foundation	Trust	Hospital,	East	Prescott	Road,
Liverpool,	L14	5AB,	UK.
Abstract
The	systemic	autoimmune/inflammatory	condition	systemic	lupus	erythematosus	(SLE)	manifests	before	the	age	of	16	years	in	10–20%	of	all	cases.	Clinical	courses	are	more	severe,	and	organ	complications	are	more
common	in	patients	with	juvenile	SLE.	Varying	gender	distribution	in	different	age	groups	and	increasing	severity	with	younger	age	and	the	presence	of	monogenic	disease	in	early	childhood	indicate	distinct	differences	in
the	pathophysiology	of	juvenile	versus	adult-onset	SLE.	Regardless	of	these	differences,	classification	criteria	and	treatment	options	are	identical.	In	this	article,	we	discuss	age-specific	pathomechanisms	of	juvenile-onset
SLE,	which	are	currently	available	and	as	future	treatment	options,	and	propose	reclassification	of	different	forms	of	SLE	along	the	inflammatory	spectrum	from	autoinflammation	to	autoimmunity.
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An	estimated	10–20%	of	all	patients	with	SLE	develop	clinical	disease	before	the	age	of	16	years	and	are	therefore	classified	as	childhood-onset	or	 juvenile-onset	SLE	(jSLE)	[7,8].	Peak	disease	onset	 in	the	 jSLE	cohort	 is
between	12	and	14	years.	Patients	with	disease	onset	before	5	years	of	age	are	very	uncommon	and	may	be	referred	to	as	early-onset	SLE	(eoSLE)	[9,10].	Of	note,	jSLE,	particularly	eoSLE	cases,	is	characterised	by	more	severe	clinical
phenotypes,	a	high	prevalence	of	pre-existing	organ	damage	at	diagnoses,	more	complications	and	 less	 favourable	outcomes	compared	 to	adult-onset	SLE	 (aSLE)	 [7–13]	(Table	1).	 The	observations	 that	 gender	distribution	 varies
between	age	groups	and	that	more	severe	phenotypes	occur	in	patients	with	jSLE,	particularly	those	with	eoSLE,	suggest	that	genetic	causes	or	risk	alleles	may	play	a	more	pronounced	role	in	jSLE.	In	patients	with	aSLE,	although
molecular	alterations,	e.g.	due	to	environmental	factors,	may	accumulate	over	time	and	finally	cause	disease	expression,	disease-causing	mutations	or	a	combination	of	risk	alleles	may	be	sufficient	to	cause	disease	in	the	paediatric	age
group	(Fig.	1).
Table	1	Monogenic	forms	of	SLE	or	‘SLE-like’	disease	(alphabetical	listing,	may	be	incomplete).
Gene Protein	product Affected	pathway Disease	phenotype Inheritance Ref.
C1Q C1q Complement	activation	(classical
pathway),	immune	clearance
SLE-like	disease	with	skin
inflammation,	glomerulonephritis,
CNS	disease,	sometimes	recurrent
infections
AR [38]
C1R C1r Complement	activation	(classical
pathway),	immune	clearance
SLE-like	disease	with	skin
inflammation,	glomerulonephritis,
sometimes	recurrent	infections
AR [39]
C1S C1s Complement	activation	(classical
pathway),	immune	clearance
AR [40]
C2 C2 Complement	activation	(classical
pathway),	immune	clearance
SLE-like	disease	with	arthritis,	skin
inflammation,	pulmonary	disease,
sometimes	recurrent	infections
AR [41,42]
C4 C4 Complement	activation	(classical
pathway),	immune	clearance
SLE-like	disease	with	variable
phenotypes,	skin	inflammation,
glomerulonephritis,	sometimes
recurrent	infections
AR [43]
Fig.	1	Model	of	SLE	pathogenesis	and	disease	progression.	The	clinical	picture	of	SLE	is	the	net	result	of	diverse,	inter-individually	variable	molecular	mechanisms.	Genetic	predisposition	is	a	key	factor	in	SLE	pathology.	However,	in	most	individuals,
individual	genetic	factors	are	not	strong	enough	to	confer	disease.	An	exception	to	this	may	be	eoSLE.	Most	likely,	the	majority	of	patients	with	eoSLE	carry	disease-causing	mutations	in	single	genes	that	mediate	early-onset	tissue	damage	and	disease
expression.	Patients	with	juvenile-onset	SLE	carry	an	increased	number	of	risk	alleles	compared	to	those	with	aSLE.	This	increased	genetic	risk	may	centrally	contribute	to	disease	onset	in	childhood	or	adolescence.	Most	patients	with	SLE	(>80%)	develop
disease	in	adulthood.	In	most	of	these	patients	with	‘classical’	aSLE,	genetic	predisposition	results	in	a	‘susceptible’	state	and	additional	factors	trigger	loss	of	tolerance,	chronic	immune	activation,	and	initially	‘subclinical’	systemic	inflammation.	For	this,
environmental	(e.g.	toxins,	UV	light,	etc.)	and	additional	endogenous	(e.g.	hormones)	factors	may	need	to	accumulate	to	trigger	loss	of	self-tolerance.	Furthermore,	additional	currently	unknown	factors	may	be	necessary	to	amplify	inflammation	and
autoimmune	processes	that	finally	result	in	tissue	damage	and	in	the	diagnosis	of	SLE.
DNASE1
DNASE1L3
DNAse1
DNAse1L3	(homologous	to	DNAse1)
Reduced	clearance	of	chromatin SLE	with	high-titre	anti-DNA
antibodies
AD
AR
[23,26]
FASLG	(Fas	ligand) FasL	(Fas	ligand) Apoptosis Autoimmune	lymphoproliferative
syndrome	(ALPS)
AD [19,21]
PRKCD	(Protein
kinase	C	delta)
PKCδ Lymphoproliferation,	spontaneous
cell	death
SLE	with	ALPS-like	phenotype AR [35–37]
SAMHD1	(SAM
domain	and	HD
domain-containing
protein	1)
Reduced	metabolisation	of	dNTPs
may	result	in	increased
retrotranscription	of	endogenous
retroelements	and	subsequent
accumulation	of	cytoplasmic	DNA
and	type	I	interferon	production
SLE,	Aicardi-Goutieres	syndrome AR [44,45]
TNFRSF6	(Tumour
necrosis	factor
receptor	super
family	member	6)
Fas	(CD95) Apoptosis Autoimmune	lymphoproliferative
syndrome	(ALPS),	autoimmune
cytopenia
AD [20]
TREX1 Trex1 Reduced	clearance	of	chromatin
(ssDNA),	activation	of	type	I
interferon	expression
Familial	chilblain	lupus	in
approximately	20%	progression	to
SLE
AR	or	AD [28–31,34,46]
AR:	autosomal	recessive;	AD:	autosomal	dominant.
In	 the	 following,	we	discuss	 the	 current	understanding	of	 jSLE	pathology	and	currently	 available	 and	 future	 therapeutic	 options	and	we	propose	 classification	of	 ‘SLE	sub-groups’	 based	 on	genetic	 risk.	We	 focus	 on	 key
concepts	and	recent	publications	rather	than	providing	an	all-inclusive	collection	of	published	reports.
Monogenic	SLE	and	‘SLE-like’	disease
Very	few	patients	suffer	from	SLE	caused	by	mutations	in	single	genes.	These	forms	are	referred	to	as	monogenic	or	Mendelian	forms	[2,3,14,15].	While	rare	mutations	in	single	genes	do	not	contribute	significantly	to	the
overall	population	heritability,	effects	can	be	devastating	in	affected	individuals.	Monogenic	SLE	has	also	provided	valuable	insights	into	disease	pathophysiology	of	‘classical’	SLE	(Table	1).	Interestingly,	most	patients	presenting	with
monogenic	 forms	 of	 SLE	 will	 (at	 least	 initially)	 not	 present	 with	 high	 titres	 of	 autoantibodies	 and	 may	 not	 exhibit	 autoreactive	 lymphocyte	 populations.	 Thus,	 at	 least	 some	 forms	 of	 monogenic	 SLE	 meet	 the	 definition	 of
autoinflammatory	disorders	that	are	caused	by	dysregulation	of	innate	immune	responses	[16,17]	(Fig.	2).
Autosomal	recessive	loss-of-function	mutations	in	upstream	components	of	the	classical	complement	pathway,	namely,	C1q,	C1r,	C1s,	C2,	C4A	and	C4B,	result	in	lupus-like	phenotypes	in	a	large	subset	of	affected	individuals
[2,3,14,18].	 Deficiencies	 of	 complement	 components	may	 promote	 autoimmune	 reactions	 and	 inflammation	 through	 several,	 incompletely	 understood	mechanisms.	 Defective	 clearance	 and	 resulting	 tissue	 deposition	 of	 immune
complexes	(C1	deficiency)	and	altered	negative	selection	of	self-reactive	B	lymphocytes	(C4	deficiency)	are	two	possible	explanations	for	systemic	inflammation	in	affected	individuals.	Aberrant	clearance	of	cellular	debris	(as	a	result	of
apoptosis	or	necrosis),	which	is	also	dependent	on	complement	activation,	has	emerged	as	a	central	mechanism	not	only	in	primary	complement	deficiencies	but	also	in	classical	SLE	[2,3,14,18].
Disturbed	apoptosis	has	been	proposed	to	be	involved	in	SLE	and	other	autoimmune/inflammatory	conditions.	Indeed,	mutations	in	the	FAS	or	FASL	genes,	which	are	key	regulators	of	activation-induced	cell	death,	result	in
autoimmune	lymphoproliferative	syndrome	(ALPS)	[2,19,20].	Furthermore,	animals	deficient	of	Fas	(MRL.lpr	mice)	develop	lupus-like	disease	with	generalised	lymphoproliferation.	In	both	humans	and	mice,	ineffective	elimination	of
autoreactive	T	lymphocytes	results	in	lupus-like	systemic	inflammation,	tissue	and	organ	damage	[21,22].
Aberrant	clearance	of	cytosolic	and/or	extracellular	nucleic	acid	can	result	in	a	lupus-like	pattern.	Mutations	in	several	genes	involved	in	sensing	or	degradation	of	nucleic	acids	have	been	reported	to	cause	monogenic	forms
of	SLE	or	related	disease	[3,14].	Impaired	degradation	and	removal	of	chromatin	components	(including	DNA)	contribute	to	autoantibody	production	and	tissue	damage.	Humans	and	mice	deficient	in	DNAse1	exhibit	accumulation	of
extracellular	chromatin,	autoantibody	production	and	subsequently	 lupus-like	disease	 [14,23–26].	Recently,	 rare	 familial	 cases	of	SLE	were	associated	with	autosomal	 recessive	mutations	 in	DNASE1L3	 (a	homologue	of	DNAse1),
resulting	in	entirely	abrogated	nuclease	activity,	extracellular	accumulation	of	DNA,	autoantibody	production,	complement	consumption	and	early-onset	SLE	[23,27].
Autosomal	dominant	mutations	 in	TREX1,	 encoding	 for	 the	3′-5'exonuclease	Trex1,	 cause	 familial	 chilblain	 lupus	 (FChL).	Clinical	 characteristics	 of	FChL	 include	Raynaud's	phenomenon,	painful	 and	 sometimes	ulcerating
chilblain	lesions.	First	symptoms	may	manifest	early	in	childhood,	and	up	to	20%	of	patients	with	FChL	progress	to	full-blown	SLE	[28–30].	In	FChL,	loss	of	function	of	Trex1	causes	cytoplasmic	accumulation	of	nucleic	acids	(single-
stranded	DNA),	which	are	sensed	by	the	nucleic	acid	sensing	machinery,	resulting	 in	type	I	 interferon	production	[31–33].	Thus,	FChL	 is	a	key	representative	of	defects	 in	cytosolic	nucleic	acid	sensing	and	processing,	which	are
currently	referred	to	as	primary	type	I	interferonopathies	[34],	some	of	which	share	clinical	characteristics	with	SLE.
Breach	of	self-tolerance	is	a	key	mechanism	in	SLE.	Though	most	central	for	immune	homeostasis,	to	date,	few	disease-causing	mutations	have	been	described,	which	specifically	alter	self-tolerance.	Homozygous	missense
mutations	in	the	PRKCD	gene,	encoding	the	protein	kinase	C	delta	(PKCδ),	result	in	abrogated	phosphorylation	and	activation	of	the	enzyme.	Peripheral	B	cells	from	patients	and	animals	deficient	of	PKCδ	exhibited	increased	cell	death
and	lymphoproliferation	in	response	to	B	cell	stimulation	through	the	B	cell	receptor	complex,	CD40	and	Toll-like	receptor	(TLR)	9	[35–37],	culminating	in	a	loss	of	self-tolerance,	lymphoproliferation	and	systemic	inflammation.
Taken	 together,	 a	 relatively	 small	number	of	 currently	known	gene	defects	 cause	monogenic	SLE	or	SLE-like	disease.	Mendelian	 forms	of	SLE	are	usually	 characterised	by	a	positive	 family	history,	 early	disease-onset	 in
childhood,	relatively	equal	gender	distribution,	severe	and	sometimes	not	‘classical’	symptoms	and	poor	response	to	‘standard’	treatment.
Risk	alleles
‘Classical’	SLE	 is	 characterised	by	 the	presence	of	high-titre	autoantibodies,	usually	against	nuclear	antigens,	 and	autoreactive	 lymphocyte	populations	 [2,3].	Most	patients	with	 jSLE	 (except	 those	with	eoSLE)	meet	 this
definition	but	may	also	show	‘mixed	patterns’	with	activation	of	both	innate	and	adaptive	immune	responses	[16,17]	(Fig.	2).
A	genetic	component	to	SLE	pathophysiology	is	emphasised	by	an	increased	risk	for	the	development	of	disease	with	an	affected	first-degree	relative	(approximately	30-fold)	and	high	rates	of	disease	concordance	in	dizygotic
(5%)	and	particularly	monozygotic	twins	(40–60%)	[2,4,6,7,15].	More	than	40	genes	have	been	associated	with	SLE	through	genome-wide	association	studies	(GWAS)	and	targeted	approaches	[47].	These	associations	are	established
when	genetic	 variants	 (usually	 single	 nucleotide	 polymorphisms	 or	 copy	 number	 variants)	 are	more	 common	 in	 patients	with	SLE	 compared	 to	matched	 healthy	 controls	 [3].	While	 very	 few	 patients	 develop	 the	 aforementioned
monogenic	forms	of	SLE,	most	individuals	carry	single	nucleotide	alterations	in	coding	or	non-coding	regions	or	copy	number	differences	of	genes	that	are	associated	with	an	increased	risk	for	SLE.	These	so-called	risk	alleles	are	by
themselves	not	‘strong’	enough	to	result	in	the	disease	without	additional	factors	(Table	2).	Of	note,	some	of	the	disease-associated	risk	alleles	are	located	in	or	around	genes	that	can	also	cause	monogenic	SLE	when	carrying	loss-of-
function	mutations	(e.g.	complement	genes,	TREX1,	etc.).
Table	2	Selection	of	susceptibility	genes	and	risk	alleles	in	SLE	(may	be	incomplete).
Pathway	affected Genomic	variants	associated	with	SLE Ref.
B	and	T	cell	activation PTPN22,	TNFSF4,	IL10,	SPRED2,	STAT4,	PXK,	AFF1,	IL12A,	BANK1, [3,15,54,60–64]
Fig.	2	Stratification	of	SLE	along	the	inflammatory	spectrum.	Forms	of	SLE	can	be	stratified	along	the	inflammatory	spectrum	proposed	by	McGonagle	and	McDermott	[17].	Rare	monogenic	forms	of	SLE	may	occur	at	either	end.	Mendelian	disease	likely
manifests	early	in	life	(eoSLE),	while	multi-factorial	disease	that	relies	on	genetic	predisposition	and	the	accumulation	of	other	factors	usually	manifests	later	in	life	(jSLE	or	aSLE).
TCF7,	SKP1,	MHC	genes,	IKZF1	and	IKZF3,	BLK,	ARID5B,	CD44,
LYN,	ETS1,	FLI1,	SH2B3,	CSK,	ELF1,	CIITA,	ITGAM,	TYK2,	ITGAM,
IKZF2,	PPP2CA,	SIAE,	CREM
Neutrophil	and	monocyte	signalling ITGAM,	ICAM,	FCGR2B,	FCGR3A,	FCGR3B,	IL10,	IRF8
TLRs	and	interferon	signalling IFIH1,	PRDM1,	UHRF1BP1,	TNFAIP3,	IRF5-TNPO3,	IRF7	and	IRF8,
SOCS1,	PRKCB,	UBE2L3,	IRAK1,	TLR7
[3,15,65]
Inflammation TNIP1 [15]
Immune	complex	processing	and	clearance FCGR2A,	FCGR2B,	FCGR3A,	FCGR3B,	ATG5,	CLEC16A,	C4,	NCF2,
LYST
[3,15,65–67]
Other/unknown ABHD6,	RAD51B,	MECP2,	RASGRP3,	TMEM39A,	PITG1,	TNXB,
JAZF1,	XKR6,	FAM167A–AS1,	WDFY4,	SMG7,	DHCR7,	NADSYN1,
SLC15A4,	PLD2,	CXorf21,	rs1167796,	rs463128,	rs7186852,
rs7197475
[3,15]
Currently	known	risk	alleles	affect	multiple	pathways	and	cell	subsets	involved	in	the	pathophysiology	of	SLE.	In	agreement	with	the	aforementioned	reports	on	monogenic	forms	of	SLE,	a	large	proportion	of	SLE-associated
risk	 alleles	 affect	 lymphocyte	 activation,	 TLR	 and	 type	 I	 interferon	 pathways,	 and	 immune	 complex	 processing	 (Table	 2).	 An	 all-inclusive	 discussion	 of	 genomic	 variants	 in	 SLE	 is	 beyond	 the	 scope	 of	 this	manuscript,	 but	 two
susceptibility	mechanisms	should	be	mentioned.
Partial	 deficiency	 of	 the	upstream	components	 of	 the	 classical	 complement	 cascade	 (C1,	C2	 and	C4)	 contributes	 to	SLE	pathology,	most	 likely	 through	 insufficient	 clearance	 of	 immune	 complexes	 and	 apoptotic	material
[3,48–51].	Furthermore,	reduced	levels	of	C4	may	result	in	increased	numbers	of	autoreactive	B	cells	in	the	periphery	secondary	to	altered	negative	selection	[52].	Copy	number	variants	(FCGR3B)	and	missense	mutations	(FCGR2A;
p.H131R,	and	FCGR3A;	F176V)	in	low-affinity	complement	receptors	are	associated	with	SLE	and	disease-related	tissue	damage	likely	through	reduced	immune	complex	clearance	and	subsequently	increased	inflammatory	responses
[53–55].
The	aforementioned	disease-causing	mutations	in	the	DNA	repair	exonuclease	Trex1	result	in	the	clinical	picture	of	FChL.	Interestingly,	0.5–3%	of	patients	with	SLE	in	Europe	and	the	USA	carry	variants	in	TREX1	[29,56,57]
and	are	at	an	increased	risk	for	neurological	manifestations,	particularly	seizures	[57].	Most	variants	associated	with	SLE	are	located	in	regions	that	are	not	responsible	for	exonuclease	activity	and	may	affect	the	ability	of	Trex1	to
associate	in	the	so-called	SET	complex.	The	SET	complex	plays	a	key	role	in	granzyme	A-mediated,	caspase-independent	cell	death,	a	process	that	morphologically	resembles	apoptosis.	This	granzyme	A-mediated	cleavage	of	NDUFS3
results	in	the	release	of	mitochondrial	superoxide.	In	response	to	this,	the	redox-sensitive	SET	complex	translocates	to	the	nucleus.	Granzyme	A	then	cleaves	the	SET	complex	components	SET,	HMGB2	and	APE2,	thereby	liberating	the
endonucleases	NM23-H1	and	Trex1,	resulting	in	DNA	damage	and	cell	death.	Through	altered	association	of	variant	Trex1,	autoreactive	lymphocytes	may	survive	longer	through	increased	resistance	to	granzyme-mediated	cell	death
[3,58].
Taken	 together,	 defined	 polymorphisms	 increase	 the	 risk	 for	 developing	 SLE	 but	 are	 usually	 not	 strong	 enough	 to	 confer	 disease.	Most	 affected	 individuals	will	 develop	 clinical	 disease	 later	 in	 life,	 potentially	 after	 the
accumulation	of	additional	disease-causing	factors	(e.g.	infections,	medication,	epigenetic	patterns,	etc.)	[4,6].	Additional	contributors	to	disease	expression	in	SLE	are	beyond	the	scope	of	this	manuscript	and	are	discussed	elsewhere
[2,4–6,15].	One	could	hypothesise	that	the	combination	of	multiple	risk	alleles	may	result	in	cumulative	effects	and	early	disease	onset,	namely,	jSLE.	Indeed,	Sawalha	et	al.	(2011)	reported	a	higher	prevalence	of	genetic	factors	in
patients	with	early	disease	onset	and	more	severe	clinical	phenotypes.	Thus,	the	accumulation	of	individual	genetic	risk	factors	may	prime	individuals	to	develop	disease	early	in	life	(jSLE)	and	develop	more	severe	clinical	patterns	and
complications	compared	to	older	patients	(aSLE)	[59].
Cellular	contributors	to	inflammation	and	tissue	damage	in	SLE
SLE	is	characterised	by	deeply	disturbed	function	and	activity	of	innate	and	adaptive	immune	cells.	Most	of	the	available	data	are	from	adult	cohorts.	Comparative	analyses	using	cells	from	patients	with	eoSLE,	other	forms	of
jSLE	and	aSLE	are	lacking	and	urgently	needed.	However,	molecular	phenotypes	in	adolescents	and	young	adults	may	be	comparable	and	will	be	summarised	in	this	article.
Neutrophilic	 granulocytes	 from	 patients	 with	 SLE	 exhibit	 several	 anomalies	 and	 are	 involved	 in	 inflammation	 and	 tissue	 damage.	 Reduced	 phagocytic	 capacities	 have	 been	 reported	 in	 patients	 with	 SLE,	 which	may
contribute	to	an	increased	risk	for	infection	and	immune	complex	deposition	[15,68].	Furthermore,	neutrophils	from	patients	with	SLE	fail	to	produce	reactive	oxygen	species	(ROS)	when	compared	to	cells	from	healthy	controls	[69].
This	may	alter	apoptosis	and	immune	complex	clearance	in	SLE.	As	neutrophils	are	short	lived	and	exist	in	rather	large	numbers,	minor	changes	to	their	apoptotic	behaviour	may	have	large	effects	on	waste	clearance	and	immune
complex	deposition	[70].
An	abnormal	subset	of	neutrophils	has	been	identified	in	patients	with	SLE.	The	so-called	low-density	granulocytes	are	characterised	by	increased	NETosis,	a	mechanism	of	cell	death	that	occurs	in	response	to	various	stimuli
including	contact	with	 infectious	agents	 and	oxidative	 stress.	 It	 involves	 the	extrusion	of	 chromatin	and	other	nuclear,	 cytoplasmic	and	granular	material	 to	 the	extracellular	 compartment.	Neutrophil	NETs	 contain	 inflammatory
cytokines,	antimicrobial	peptides,	enzymes	and	nucleosomes,	which	represent	key	autoantigens	in	SLE	[71–74].	Furthermore,	neutrophil	NETs	contribute	to	the	expression	of	type	I	interferons	by	plasmacytoid	dendritic	cells	(pDCs)
through	the	activation	of	TLR9.	In	turn,	type	I	interferons	prime	neutrophils	for	NETosis,	which	suggests	a	positive	feedback	loop	that	increases	inflammation	and	tissue	damage	in	SLE	[15,75,76].
Moreover,	monocytes	 from	 patients	 with	 SLE	 exhibit	 altered	 function.	 They	 express	 increased	 amounts	 of	 proinflammatory	 CC	 chemokine	 ligand	 2	 (CCL2),	 which	 is	 regulated	 by	 LPS	 or	 interferons	 [77].	 Furthermore,
monocytes	from	patients	with	SLE	exhibit	epigenetic	patterns	allowing	for	increased	expression	of	tumour	necrosis	factor	(TNF)-α	[78],	which	may	contribute	to	monocyte	maturation	and	downstream	pro-inflammatory	cytokine	and
chemokine	expression	[4].	Indeed,	infiltration	of	monocytes	to	the	kidneys	mirrors	inflammation	and	tissue	damage	and	even	allows	prognostic	assessment	[77,79,80].	Thus,	monocytes	and	tissue	macrophages	may	play	a	critical	role	in
the	development	of	tissue	damage	in	SLE.
Dysregulated	antigen	presentation	by	dendritic	cells	(DCs)	may	contribute	to	the	loss	of	self-tolerance	of	B	and	T	cells	 in	SLE.	Various	DC	anomalies	have	been	reported	in	patients	with	SLE,	including	a	shift	away	from
classical	DC	phenotypes	toward	increased	numbers	of	plasmacytoid	DCs	(pDCs),	the	main	cellular	source	of	type	I	interferons	[81].	Plasmacytoid	DCs	take	up	immune	complexes	through	low-affinity	FcγR2a	receptors.	Presentation	to
endosomal	TLRs	7	and	9	induces	interferon	expression	[82].	Therefore,	this	pathway	may	centrally	contribute	to	the	so-called	type	I	interferon	signature	in	‘classical’	SLE	and	complement	deficiencies	[16].	Furthermore,	conventional
DCs	in	patients	with	SLE	appear	to	promote	autoreactivity	rather	than	self-tolerance.	In	turn,	activated	T	lymphocytes	also	promote	type	I	interferon	expression	by	pDCs	[15,83,84].
Significant	dysregulation	of	T	lymphocyte	 function	is	a	hallmark	of	SLE,	and	several	of	the	aforementioned	risk	alleles	influence	T	cell	function	(Table	2).	T	cells	in	patients	with	SLE	are	characterised	by	altered	cytokine
expression,	reduced	numbers	of	regulatory	phenotypes,	and	increased	numbers	of	effector	T	cells	[2–6,85–88].	In	T	cells	from	patients	with	SLE,	the	‘normal’	CD3ζ	chain	is	replaced	by	the	FcRγ	chain.	This	results	in	interactions	and
activation	of	SYK	tyrosine	kinases	instead	of	the	physiological	activation	of	ZAP-70,	resulting	in	overactivated	T	cell	receptor	signalling	pathways	[2,89,90].	Regardless	of	their	increased	activation	status,	T	cells	from	patients	with	SLE
fail	to	express	IL-2,	which	is	caused	by	several	molecular	disturbances	orchestrated	by	the	transcription	factor	cAMP	response	element	modulator	(CREM)-α	[2,86,87,91].	Reduced	IL-2	expression	may	contribute	to	impaired	activation-
induced	cell	death,	reduced	cytotoxicity	of	CD8+	T	cells	and	increased	numbers	of	effector	T	cells	in	SLE.	Indeed,	T	cells	from	patients	with	SLE	exhibit	effector	phenotypes	in	the	CD4+	and	CD3+CD4−CD8−	‘double	negative’	(DN)	T
cell	compartment	that	are	characterised	by	the	increased	expression	of	IL-17A	[3,86,92–95].	The	numbers	of	DN	T	cells	are	increased	in	the	peripheral	blood	of	juvenile	and	adult	patients	with	SLE,	and	the	cells	infiltrate	the	kidneys
where	they	produce	pro-inflammatory	IL-17A,	a	central	contributor	to	tissue	damage	[3,92–94,96].	Regulatory	T	cell	(Tregs)	phenotypes	are	reduced,	and	their	function	is	impaired	in	patients	with	SLE.	Under	physiological	conditions,
both	B	and	T	lymphocytes	are	subject	to	regulation	by	Tregs.	Of	note,	Treg	differentiation	is	dependent	on	IL-2,	which	fails	to	be	expressed	in	SLE.	Treatment	of	patients	with	SLE	and	lupus-prone	mice	with	recombinant	IL-2	resulted	in
an	increase	in	Tregs	numbers,	restored	their	function,	and	limited	pro-inflammatory	cytokine	expression	from	effector	DN	T	cells	[97–99].
Although	 SLE	 is	 a	 highly	 heterogeneous	 disease,	 most	 patients	 with	 SLE	 exhibit	B	 cell	 activation	 and	 high	 titres	 of	 autoantibodies	 directed	 against	 nuclear	 antigens.	 Autoantibody	 production	 may	 be	 genetically
predetermined	and/or	triggered	by	the	overabundance	of	extracellular	chromatin	components	(detailed	above)	[4,15,16,59,100].	Furthermore,	B	cell	tolerance	can	also	be	breached	by	the	exposure	to	cytokines	(including	the	B	cell
promoting	factors	BAFF/BLyS)	[101,102].	Indeed,	studies	in	humans	have	demonstrated	both	acquired	environmental	and	heritable	genetic	contributions	to	autoreactivity	of	B	cells	with	gradually	increasing	autoreactive	capacities	of	B
cells	 in	autoimmune/inflammatory	disease	 [15,103–107].	Autoantibody	production	 is	a	key	event	 in	SLE.	 It	 induces	 inflammatory	responses	 through	the	 formation	of	 immune	complexes,	which	activate	complement,	 low-affinity	Fc
receptors,	and	a	wide	range	of	immune	cells	[2,15].
Complications	of	jSLE	in	light	of	‘age-specific’	pathomechanisms
Inflammatory	organ	involvement	and	tissue	damage	is	more	common	in	jSLE	compared	to	aSLE.	Furthermore,	organ	complications	frequently	exist	already	at	the	time	of	diagnosis	in	patients	with	jSLE	[7,9,10].	Given	the
aforementioned	contribution	of	genetic	factors	to	early	disease	presentation	and	their	statistical	association	with	more	severe	disease	courses	[59],	it	is	tempting	to	hypothesise	that	genetic	factors	may	contribute	to	specific	organ
manifestations	and	complications,	potentially	allowing	for	patient	stratification.	In	this	case,	genomic	associations	may	aid	in	assessing	individual	risk	and	offering	targeted	treatment	options.	Indeed,	individual	genetic	variants	have
been	associated	with	organ	involvement	and/or	disease	outcomes.	SLE-associated	variants	in	TREX1	indicate	increased	risk	for	neurological	manifestations	[57],	and	certain	Fcγ	receptor	variants	are	more	common	in	patients	with
severe	lupus	nephritis	(FCGR3A)	[67].	Although	we	are	only	at	the	very	beginning	of	understanding	the	exact	contribution	of	genomic	variants	to	disease	expression,	phenotypes	and	outcomes,	available	reports	promise	potential	for
patient	stratification	based	on	impaired	molecular	mechanisms	allowing	for	individualised	management	[3].
Treatment	options	in	jSLE
Treatment	of	jSLE	is	complex	and	less	standardised	compared	to	aSLE.	Regardless	of	differences	in	the	pathophysiology	of	eoSLE	vs.	jSLE	vs.	aSLE,	classification	criteria	and	commonly	used	treatment	options	are	identical,
and	age-specific	differences	fail	to	be	appreciated.	Another	layer	of	complexity	is	added	in	jSLE	with	the	occurrence	of	potentially	toxic	events	and	treatment-related	side	effects	alongside	the	ongoing	physical,	mental	and	psychosocial
developmental	processes	of	childhood.	Patients	with	JSLE	require	higher	doses	of	corticosteroids	and	immune	suppressive	drugs,	which	is	likely	due	to	alternative	pathomechanisms	and	higher	incidence	of	tissue	and	organ	damage	at
diagnosis	and	during	the	disease	course	[3,7,9,10]	than	in	aSLE.
To	 provide	 guidance	 and	 to	 optimise	 and	 harmonise	 diagnostic	 approaches	 and	 treatment	 of	 patients	with	 jSLE,	 the	 SHARE	 (Single	Hub	 and	Access	 point	 for	 paediatric	 Rheumatology	 in	 Europe)	 initiative	 has	 provided
evidence-based	consensus	recommendations	for	jSLE,	lupus	nephritis	and	disease-associated	anti-phospholipid	syndrome	[108–110].
Conventional	immune	modulation	or	suppression
Glucocorticoids	are	the	backbone	of	jSLE	treatment	in	the	acute	phase.	Strong	and	rapid	immunosuppressive	effects	through	inhibition	of	prostaglandin	and	cytokine	production,	inhibition	of	cell	proliferation	and	induction	of
apoptosis	of	B	and	T	lymphocytes	as	well	as	macrophages	are	the	main	events.	Multiple	studies	demonstrated	improved	survival	with	corticosteroid	use.	However,	steroid	use	must	be	limited	because	of	significant	toxicity	and	side
effects	including	but	not	limited	to	reduced	bone	density,	metabolic	syndromes,	hypertension,	dysphoria,	glaucoma,	cataract	and	increased	risk	for	infection	[111–116].
Unless	 contraindicated	 in	 individual	 patients,	 anti-malarial	medications	 should	 be	 introduced	 in	 all	 patients	 with	 jSLE	 [108,110].	 In	 jSLE,	 usually	 hydroxychloroquine	 and	 in	 some	 countries	 chloroquine	 are	 used.	 Our
understanding	of	their	mode	of	action	is	very	limited.	Both	medications	appear	to	affect	phagocytosis	and	leukocyte	migration	and	to	reduce	the	activation	of	TLRs	[117,118].	Antimalarial	medications	reduce	the	frequency	of	disease
flares,	delay	the	onset	of	further	symptoms	in	early	disease	and	prevent	thromboembolic	events	[116,119,120].	During	pregnancy	(in	all	women	with	Ro/SSA	or	La/SSB	antibodies,	not	only	patients	with	SLE),	hydroxychloroquine	may
reduce	the	risk	of	congenital	hearth	block	associated	with	neonatal	lupus	syndrome	[121].	Toxicity	and	side	effect	are	usually	limited.	Retinal	toxicity,	although	a	big	concern	for	most	providers	particularly	in	young	patients,	is	a	rare
event	[122].
The	 alkylating	 agent	 cyclophosphamide	 (CPM)	 has	 strong	 anti-proliferative	 and	 cytotoxic	 effects	 on	 immune	 cells.	 It	 is	 used	 for	 severe	 jSLE	 manifestations,	 particularly	 CNS	 disease	 and	 proliferative	 lupus	 nephritis.
Particularly	in	childhood,	intravenous	pulse	therapy	is	preferred	because	of	likely	reduced	side	effects	compared	to	oral	treatment	schemes	[123,124].	Severe	side	effects	and	toxicity	may	limit	the	use	of	CPM	and	include	opportunistic
infections,	secondary	malignancies,	renal	and	bladder	toxicity,	ovarian	failure	and	azoospermia	[116,125–127].
Mycophenolate	mofetil	(MMF)	inhibits	DNA	synthesis,	resulting	in	reduced	proliferation	of	B	and	T	lymphocytes.	Because	of	its	lower	side-effect	profile	compared	to	CMP,	MMF	is	used	for	induction	and	maintenance	treatment
in	jSLE,	particularly	with	renal	involvement	[128–132].	Indeed,	MMF	may	even	be	superior	to	CMP	induction	therapy	in	African	Americans	and	Hispanics	with	SLE	[133].	MMF	displays	relatively	limited	side	effects	(gastrointestinal
complaints,	sometimes	leukopenia	and/or	infections);	therefore,	MMF	is	commonly	used	in	the	treatment	of	jSLE	and	may	even	replace	CPM	in	lupus	nephritis	induction	treatment	[110].
Azathioprine	(AZA)	is	a	pro-drug	that	on	activation	becomes	6-mercaptopurine,	a	purine	analogue.	This	inhibits	DNA	synthesis	and	lymphocyte	proliferation	[134].	For	induction	treatment,	AZA	is	inferior	to	CMP	and	MMF,	but
it	can	be	useful	as	maintenance	treatment	in	lupus	nephritis	[129,135,136].	AZA	is	metabolised	by	the	enzyme	thiopurin	methyltransferase	(TPMT)	whose	activity	is	subject	to	inter-individual	variability	secondary	to	polymorphisms	in
the	TMPT	gene.	Although	toxicity	and	side	effects	(particularly	myelosuppression,	hepatotoxicity,	infections	and	pancreatitis)	are	generally	more	common	in	AZA	compared	to	MMF,	an	individual's	risk	can	be	assessed	by	screening	for
TPMT	polymorphisms	of	the	TPMT	enzyme	activity	before	treatment	initiation	[116,134].
The	folic	acid	analogue	methotrexate	(MTX)	inhibits	purine	synthesis	and	adenosine	deaminase	activity.	It	has	anti-proliferative	effects	on	lymphocytes	and	modulates	pro-inflammatory	cytokine	expression.	Effects	of	MTX	in
jSLE	 are	 usually	 modest,	 and	 its	 use	 is	 limited	 to	 arthritis,	 skin	 inflammation	 and	 sometimes	 diseases	 associated	 with	 the	 CNS.	 Treatment-associated	 side	 effects	 include	 nausea,	 hepatotoxicity,	 pulmonary	 damage	 and	 rarely
myelosuppression	[137–139].
Available	target-directed	approaches
The	presence	of	autoantibodies,	altered	clearance	of	immune	complexes	and	the	fact	that	B	and	T	cells	interact	and	co-stimulate	one	another	have	resulted	in	the	introduction	of	B	cell-directed	treatment	strategies	in	SLE.
Rituximab	(RTX),	a	chimeric	antibody	directed	against	CD20,	depletes	circulating	B	cells	but	does	not	affect	plasma	cells	[116,140,141].	While	approved	for	the	treatment	of	other	autoimmune/inflammatory	conditions,	approval	for	SLE
treatment	is	lacking,	in	part	because	of	difficulties	arising	from	the	design	of	the	initial	study	and	subsequent	failure	for	it	to	reach	its	primary	end	points	[142,143].	However,	in	a	number	of	post	hoc	analyses	and	large	case	collection
studies,	 including	 the	paediatric	 age	group,	RTX	has	been	demonstrated	 to	have	 steroid-sparing	effects,	 to	 reduce	 the	number	of	 flares	 and	 to	be	 effective	 in	 otherwise	 treatment-resistant	 cases	 of	 lupus	nephritis	 [116,143–147].
Although	usually	quite	well-tolerated,	adverse	events	and	toxicity	can	occur.	Allergic	reactions,	infections	and	transitory	and	persistent	hypo-	or	agammaglobulinaemia	have	been	reported	[148–150].
Activation	and	function	of	B	lymphocytes	can	be	targeted	by	inhibition	of	the	cytokine	B	lymphocyte	stimulator	(BLyS)	or	B	cell	activating	factor	(BAFF)	with	belimumab,	a	humanised	monoclonal	antibody	against	BLyS/BAFF.
Recently,	regardless	of	relatively	mild	effects	 in	most	patients,	belimumab	was	approved	for	the	use	in	aSLE	excluding	patients	with	CNS	involvement	or	active	lupus	nephritis.	Treatment	with	belimumab	results	 in	a	reduction	of
autoantibody	titres	and	partial	B	cell	depletion.	Thus,	it	may	be	hypothesised	that	belimumab	may	be	a	promising	option	in	patients	who	received	RTX	to	sustain	anti-B	cell	effects.	Clinical	experience	suggests	that	belimumab	may	be
particularly	effective	in	patients	with	high	titres	of	autoantibodies	and	fatigue	[102,151–154].
Future	direction	in	the	treatment	of	jSLE
Individualised	and	target-directed	treatment	is	a	central	goal	in	modern	medicine.	Currently,	several	biologic	treatment	options	are	already	available	for	the	use	in	the	paediatric	age	group.	However,	none	of	them	have	been
sufficiently	 tested	or	approved	 in	aSLE	or	 jSLE.	Blockade	of	 IL-6	signalling	with	 tocilizumab	 showed	 significant	 improvement	 in	 a	 small	 series	 of	 patients	with	SLE	 [155,156].	Inhibition	 of	 TNF-α	 is	 a	well-established	 concept	 in
paediatric	rheumatology,	and	patients	with	jSLE	and	arthritis	in	particular	may	benefit	from	TNF	inhibition.	However,	development	of	dsDNA	antibodies	and	drug-induced	lupus	are	known	side	effects	of	at	least	some	TNF	inhibitors
[157–159],	leading	to	caution	in	the	use	of	TNF	inhibitors	in	SLE.	Interleukin-17	plays	a	central	role	in	the	development	of	tissue	inflammation	and	organ	damage	through	the	chemo-attraction	of	additional	immune	cells.	Effector	T	cells
are	the	main	source	of	IL-17,	and	IL-23	plays	a	role	in	their	priming.	Thus,	blockade	of	IL-17	or	IL-23	may	be	beneficial	in	SLE.	However,	although	IL-17-	and	IL-23-directed	treatments	have	been	approved	for	the	treatment	of	arthritis
and/or	psoriasis,	they	have	not	been	tested	in	SLE	yet	[3,160,161].
As	mentioned	 above,	 altered	 expression	 and	 activation	 of	 protein	 kinases	 (CaMK4,	SYK,	 etc.)	 and	 transcription	 factors	 (CREMα,	 Stat	 family	 transcription	 factors)	 promise	 potential	 as	 therapeutic	 targets	 in	SLE.	 Indeed,
inhibitors	of	Janus	kinases	(JAK),	Stat	phosphorylation	and	SYK	kinases	are	already	available	and	are	awaiting	further	pre-clinical	and/or	clinical	testing	[162–164].	In	some	rare	monogenic	forms	of	SLE	or	‘SLE-like’	disease,	small	case
series	and/or	individual	case	reports	already	indicate	beneficial	effects	of	JAK	inhibition	[165–167].
Finally,	tissue	protection	 is	a	 significant	concern	 in	 inflammatory	disease.	While	established	 in	other	 inflammatory	conditions	 (e.g.	myocardial	 remodelling	after	 infarctions)	 [168],	 this	concept	has	not	been	appreciated	 in
systemic	autoimmune/inflammatory	disorders	to	the	same	extent.	However,	more	recently,	kidney	protection	through	ACE	inhibitor	treatment	[169,170]	and	the	use	of	antioxidants	(e.g.	acetylcysteine)	have	been	discussed	[171,172].
Further	studies	targeting	tissue	factors	that	may	contribute	to	organ	damage	are	urgently	needed	to	allow	sufficient	and	individualised	prevention	of	irreversible	damage	and	organ	failure.
Concluding	remarks
Juvenile-onset	 SLE	 is	 characterised	 by	 severe	 presentations	 and	 aggressive	 clinical	 courses	 with	 high	 disease	 activity	 resulting	 in	 tissue	 damage.	 In	 analogy	 to	 other	 inflammatory	 conditions,	 jSLE	 can	 (although	 yet
incompletely)	be	stratified	along	the	‘inflammatory	spectrum’	from	autoinflammation	to	autoimmunity	with	monogenic	autoinflammatory	disorders	at	one	end	and	‘classical’	disease	courses	at	the	other	end	(Fig.	2).	Although	affecting
a	small	subset	of	patients,	the	identification	of	rare	monogenic	forms	(e.g.	complement	deficiencies)	has	improved	our	understanding	of	the	more	common	forms	of	SLE.	In	most	instances,	monogenic	disease	manifests	early	in	life	and
is	characterised	by	an	almost	equal	gender	distribution,	while	adolescent	patients	with	jSLE	will	most	likely	develop	‘classical’	multi-factorial	disease.	The	identification	of	risk	alleles	and	their	increased	abundance	in	patients	with
jSLE	promise	potential	for	future	patient	stratification	and	the	introduction	of	individualised,	target-directed	treatment	options.	To	achieve	this,	international	collaborations	are	required	to	promote	meaningful	research	in	a	rare	but
debilitating	disease.
Practice	Points
• In	SLE,	age	frequently	inversely	correlates	with	disease	severity,	with	patients	with	jSLE	more	commonly	developing	complications	compared	to	those	with	aSLE
• Patients	with	early-onset	SLE	frequently	exhibit	monogenic	disease	and	do	not	have	detectable	autoantibodies
• Patients	with	jSLE	require	higher	doses	of	corticosteroids	and	immune	suppressants	than	those	with	aSLE
• Harmonisation	of	jSLE	treatment	is	required,	and	the	SHARE	initiative	has	recently	developed	helpful	international	consensus	recommendations
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